5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab ...
5 December 2022 - A redesign of consumer cost sharing in the US is important to accelerate the adoption of biosimilars ...
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
2 November 2022 - There is a hint of a major added benefit compared to chemotherapy with cisplatin or carboplatin, each ...
25 October 2022 - Digitisation has potential when it comes to making clinical development for the care of rare diseases more ...
26 October 2022 - The German regulation of pricing and reimbursement of pharmaceuticals is probably one of the most complicated legal ...
4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...
5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is ...
15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...
8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...
30 August 2022 - In this cohort study comparing 599 medicine approvals in the US and Germany between 2004 and 2018, ...
17 August 2022 - The IQWiG has published its 2021 annual report today. ...
1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality ...
19 July 2022 - On 8 July 2022, the German Health Ministry has officially shared the second edition of a new ...
2 June 2022 - Preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is available. Please submit ...